Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced data demonstrating a…

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma - Iovance Biotherapeutics (NASDAQ:IOVA)

SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor

Real-World Data with Amtagvi Show High Response Rates in Advanced Melanoma

Patients with advanced melanoma experienced high response rates when treated with commercial Amtagvi in a real-world clinical study.